Loading stock data…
$59.51-0.31 (-0.52%)
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Exelixis, Inc. in the Healthcare sector is trading at $59.51 with a market capitalization of $14.0B. Wall Street consensus targets $54.87 (15 analysts), implying a -7.8% move over the next 12 months. The stock is currently near its 52-week high of $61.66, remaining 20.0% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $628.69M↑ | $610.81M↑ | $598.66M↑ | $597.75M↑ | $568.26M |
| Gross Profit | $608.03M↑ | $590.86M↑ | $572.18M↓ | $579.18M↑ | $548.79M |
| Operating Income | $248.41M↓ | $251.34M↑ | $235.91M↓ | $256.36M↑ | $213.58M |
| Net Income | $212.05M↑ | $210.47M↓ | $244.53M↑ | $193.58M↑ | $184.85M |
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced r...